AVEO Pharmaceuticals Inc. (AVEO)

0.72
NASDAQ : Health Technology
Prev Close 0.72
Day Low/High 0.70 / 0.73
52 Wk Low/High 0.49 / 3.59
Avg Volume 6.60M
Exchange NASDAQ
Shares Outstanding 160.74M
Market Cap 115.81M
P/E Ratio N/A
Div & Yield N.A. (N.A)
AVEO Announces Timing For Conference Call To Discuss Year-End 2013 Financial Results And Provide Strategic Update For 2014

AVEO Announces Timing For Conference Call To Discuss Year-End 2013 Financial Results And Provide Strategic Update For 2014

AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014.

AVEO And Astellas To End Worldwide Collaboration & License Agreement For Development And Commercialization Of Tivozanib

AVEO And Astellas To End Worldwide Collaboration & License Agreement For Development And Commercialization Of Tivozanib

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational...

AVEO And Astellas Discontinue Phase 2 Trial Of Tivozanib In Breast Cancer

AVEO And Astellas Discontinue Phase 2 Trial Of Tivozanib In Breast Cancer

AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc.

Six charts that show why this market is overvalued

Six charts that show why this market is overvalued

By any number of measures this market is getting pricey.

Biotech 2013 by the Numbers: A Blockbuster Year

Biotech 2013 by the Numbers: A Blockbuster Year

The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.

The Worst Biotech CEO of 2013 Is...

The Worst Biotech CEO of 2013 Is...

Vical's Vijay Samant is this year's CEO loser by a wide margin.

AVEO Provides Update On Interim Analysis From Tivozanib Trial In Colorectal Cancer

AVEO Provides Update On Interim Analysis From Tivozanib Trial In Colorectal Cancer

AVEO Oncology (NASDAQ: AVEO) today announced that data from a planned interim analysis of the Phase 2 BATON ( Biomarker  Assessment of  Tivozanib in  ONcology) study in patients with colorectal cancer...

Your Vote Counts: Who Is the Worst Biotech CEO of 2013?

Your Vote Counts: Who Is the Worst Biotech CEO of 2013?

Amarin, Ariad, Vical, Dendreon and Aveo. You get to decide which CEO deserves to wear the badge of shame.

AVEO Reports Third Quarter 2013 Financial Results

AVEO Reports Third Quarter 2013 Financial Results

AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results.

5 Biotech Stocks Under $10 for Your Watch List

5 Biotech Stocks Under $10 for Your Watch List

Keep an eye on these under-$10 biotech stocks.

AVEO Oncology To Present At The Morgan Stanley Global Healthcare Conference

AVEO Oncology To Present At The Morgan Stanley Global Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.

Aveo: Anatomy Of A Trade Gone Wrong

Aveo: Anatomy Of A Trade Gone Wrong

The FDA’s rejection of Aveo's Tivozanib is a stunner.

AVEO Oncology To Present At The Canaccord Genuity 33rd Annual Growth Conference

AVEO Oncology To Present At The Canaccord Genuity 33rd Annual Growth Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 33 rd Annual Growth Conference on Thursday, August 15, 2013 at 2:00 p.

AVEO Reports Second Quarter 2013 Financial Results

AVEO Reports Second Quarter 2013 Financial Results

AVEO Oncology (NASDAQ: AVEO) today reported second quarter 2013 financial results.

AVEO: Insiders Vs. Shorts

AVEO: Insiders Vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 06/28/2013 settlement date, and AVEO Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 5.59 "days to cover" versus the median component at 3.80.

FDA's Flawed Call On Aveo's Tivozanib

FDA's Flawed Call On Aveo's Tivozanib

The FDA has let down renal cancer patients with its Tivozanib decision.

The 5 Dumbest Things on Wall Street This Week: June 7

The 5 Dumbest Things on Wall Street This Week: June 7

Scotts Miracle-Gro CEO swears like a sailor, Aveo sinks like the Titanic, Sprint's captain tries to capsize the Dish CEO's offer and more.

5 Dumbest Things on Wall Street

5 Dumbest Things on Wall Street

Scotts Miracle-No!, Synta's Sorrow and Google's Porn Problem highlight Gregg Greenberg's 5 Dumbest list this week.

Aveo's Future Depends on Triple-Negative Breast Cancer

Aveo's Future Depends on Triple-Negative Breast Cancer

Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.

Aveo Fires 140 Workers As Punishment For CEO's Incompetence

Aveo Fires 140 Workers As Punishment For CEO's Incompetence

The failure of a kidney cancer drug won't stop Aveo executives from cashing future paychecks.

Aveo Chairman: Expect 'Consequences" From Kidney Cancer Drug Debacle

Aveo Chairman: Expect 'Consequences" From Kidney Cancer Drug Debacle

Status quo reigns at struggling Aveo's shareholder meeting, but will planned changes include executive turnover?

2013 FDA Drug Approval Calendar

2013 FDA Drug Approval Calendar

An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.

Aveo Screwed Up but Its Kidney Cancer Drug Is Real

Aveo Screwed Up but Its Kidney Cancer Drug Is Real

At some point, investors will give Aveo credit for tivozanib, says David Sobek.

3 Health Care Stocks Under $10 to Watch

3 Health Care Stocks Under $10 to Watch

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Bubble Fears Amid Relentless Market Climb

Bubble Fears Amid Relentless Market Climb

Strategists predict equity markets will be propelled higher with one warning of a bubble poised to be popped.

Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal

Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal

Heads need to roll at Aveo because of the FDA's thrashing of the company's kidney cancer drug.

Leaders of <I>TheStreet's</I> Drug Approval Contest

Leaders of TheStreet's Drug Approval Contest

This group of contestants have nearly perfect records picking FDA and European drug approvals.

Stock Futures Eye Rebound on ECB Stimulus, U.S. Data

Stock Futures Eye Rebound on ECB Stimulus, U.S. Data

Stock futures are looking to rebound from losses in the prior session.

Aveo, Delcath FDA Panel Live Blog

Aveo, Delcath FDA Panel Live Blog

Join TheStreet's Adam Feuerstein as he live blogs FDA advisory panels for Aveo Oncology and Delcath Systems

TheStreet Quant Rating: D- (Sell)